<?xml version="1.0" encoding="UTF-8"?>
<fn-group class="fn-group">
 <fn fn-type="financial-disclosure" class="fn">
  <p class="p">
   <bold class="bold">Funding.</bold> This work was funded by grants from the UK Biotechnology and Biological Sciences Research Council (BB/M022374/1; BB/P027431/1; BB/R000697/1; BB/S507532/1) (RH, PP, and CJ); The UK Medical Research Council (MR/K015826/1) (RH, JM, and MM); The Wellcome Trust (203276/Z/16/Z) (RH); the MRC Programme Grant (MC_UU12018/7) (JM); The European Research Council (649101-UbiProPox) (JM); The MRC Programme Grant (MC_U12016/1) (MM); DA has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Sk≈Çodowska-Curie grant agreement No. 750673. CJ was funded by a Commonwealth scholarship, funded by the UK government.
  </p>
 </fn>
</fn-group>
